Investigation to explore how duocarmycin prodrugs bioactivated by cytochrome P450 enzymes can be used in combination therapy to treat breast cancer cells

被引：0
|
作者：
Denasio, Enrica
Shnyder, Steven D.
Morais, Goreti R.
Martin, Stewart G.
Pors, Klaus
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2683
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tumor-selective bioactivation of duocarmycin bioprecursors by cytochrome P450 enzymes provides an opportunity to treat drug-resistant breast cancer cells
    Shnyder, Steven D.
    Loadman, Paul M.
    Sutherland, Mark
    Sheldrake, Helen M.
    Searcey, Mark
    Patterson, Laurence H.
    Pors, Klaus
    [J]. CANCER RESEARCH, 2015, 75
  • [2] Designing cytochrome P450 enzymes for use in cancer gene therapy
    Carrera-Pacheco, Saskya E.
    Mueller, Alexander
    Puente-Pineda, Juan A.
    Zuniga-Miranda, Johana
    Guaman, Linda P.
    [J]. FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2024, 12
  • [3] Role of Cytochrome P450 Enzymes in the Maintenance of Breast Cancer Metastasized to the Bone
    Chaudhari, Sonal
    Esteb, Christopher
    Chang, Yu-Ting
    Jones, Richard
    [J]. OBSTETRICS AND GYNECOLOGY, 2019, 133 : 49S - 49S
  • [4] Potential of Cytochrome P450, a Family of Xenobiotic Metabolizing Enzymes, in Cancer Therapy
    Singh, Ragini D. D.
    Avadhesh, Avadhesh
    Sharma, Gaurav
    Dholariya, Sagar
    Shah, Rima B. B.
    Goyal, Bela
    Gupta, Subash Chandra
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2023, 38 (10-12) : 853 - 876
  • [5] Use of cytochrome P450 interacting medications in the setting of adjuvant therapy for breast cancer
    Njiaju, U. O.
    Kolesar, J. M.
    Johnston, S. A.
    Eickhoff, J. C.
    Osterby, K. R.
    Poggi, L. E.
    Tevaarwerk, A. J.
    Milholland, R. J.
    Oliver, K. A.
    Heideman, J. L.
    Wisinski, K. B.
    [J]. CANCER RESEARCH, 2012, 72
  • [6] Pyridinyl 4-(2-oxoalkylimidazolidin-1-yl)benzenesulfonates and their hydrochloride salts as novel water soluble antimitotic prodrugs bioactivated by cytochrome P450 1A1 in breast cancer cells
    Ouellette, Vincent
    Bouzriba, Chahrazed
    Chavez Alvarez, Atziri Corin
    Bruxelles, Quentin
    Hamel-Cote, Genevieve
    Fortin, Sebastien
    [J]. RSC MEDICINAL CHEMISTRY, 2024,
  • [7] Nobiletin bioactivation in MDA-MB-468 breast cancer cells by cytochrome P450 CYP1 enzymes
    Surichan, Somchaiya
    Arroo, Randolph R.
    Ruparelia, Ketan
    Tsatsakis, Aristidis M.
    Androutsopoulos, Vasilis P.
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2018, 113 : 228 - 235
  • [8] Pharmacogenetics of cytochrome P450 enzymes and MDR1 in breast cancer patients treated with doxorubicin and cyclophosphamide
    Lee, Johanne S.
    Sludden, Julieann
    Griffin, Melanie J.
    Erb, Sharon
    Verrill, Mark W.
    Sumpter, Kate Anne
    Boddy, Alan V.
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [9] 4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamide salts: Novel hydrosoluble prodrugs of antimitotics selectively bioactivated by the cytochrome P450 1A1 in breast cancer cells
    Ouellette, Vincent
    Alvarez, Atziri Corin Chavez
    Bouzriba, Chahrazed
    Hamel-Cote, Genevieve
    Fortin, Sebastien
    [J]. BIOORGANIC CHEMISTRY, 2023, 140
  • [10] Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes
    Androutsopoulos, Vasilis P.
    Papakyriakou, Athanasios
    Vourloumis, Dionisios
    Tsatsakis, Aristidis M.
    Spandidos, Demetrios A.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2010, 126 (01) : 9 - 20
12345